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Abstract 
 
Background: Piroxicam exhibits low oral bioavailability due to its meagre solubility in water. 
The intent of the study described below was to ameliorate bioavailability of the drug by employing 
a solubility-enhancing encapsulation technique. 
Methods: Seven samples were formulated with piroxicam and gelatin using both the solvent 
evaporation method and electrospraying method together. Evaluation of solubility and release rate 
in water, and assessment of bioavailability in rats were carried out in comparison with piroxicam 
plain drug powder (PPDP). Other in vitro explorations were accomplished using powder X-ray 
diffraction (PXRD) analysis, differential scanning calorimetry (DSC), thermogravimetric analysis 
(TGA), scanning electron microscopy (SEM) and Fourier transform infrared (FTIR) spectroscopy. 
Results: All the piroxicam-loaded gelatin-nanocontainers (PLGNs) enhanced solubility and 
release of the payload in water. In particular, a PLGN formulation consisting of piroxicam and 
gelatin at 1/8 (w/w) ratio presented about 600-times greater solubility of the drug than that shown 
by PPDP. Moreover, 85.12 ± 10.96% payload was released from this formulation in 10 min which 
was significantly higher than that dissolved from PPDP in 10 min (11.81 ± 5.34%). The drug 
content, drug loading and encapsulation efficiency of this formulation were 93.41± 0.56%, 10.45± 
0.06% and 66.74± 6.87%, respectively. The drug loaded in PLGNs existed in the amorphous state 
as confirmed by XRD and DSC analyses, and it was more stable when analyzed by TGA. 
Moreover, FTIR spectroscopic analysis suggested non-existence of any piroxicam-gelatin 
interaction in the formulation. In the SEM image, PLGNs appeared as round-shaped and smooth-
surfaced particles, exhibiting a particle size of <1000 nm. Amelioration in bioavailability of 
piroxicam with the above-mentioned PLGN formulation was 4-fold as compared to that with 
PPDP. 
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Conclusion: The PLGN formulation fabricated with piroxicam and gelatin at 1/8 (w/w) might be 
a promising system for enhanced biopharmaceutical performance of the drug. 
Keywords: aqueous solubility; electrospraying; gelatin encapsulation; nanocontainers; oral 
bioavailability; piroxicam   
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Introduction 
 
Piroxicam, an anti-inflammatory and analgesic substance, is prescribed to mitigate pain 
and associated inflammation. In particular, it is useful in the treatment and management of pain 
accompanied by rheumatoid arthritis and osteoarthritis.1 It impedes the activity of both 
cyclooxygenase (COX) type I and COX type II enzymes; therefore, formation of prostaglandins 
(PGs) is ceased.2 PGs are a group of physiologically active lipids which induce pain and agony. 
Some interactions of piroxicam with other drugs have been reported as well. For example, when 
administered along with cadmium, it exhibits more toxicity.3 On the other hand, when co-
administered with rosuvastatin, its adverse effects such as peptic ulceration and hepatorenal 
damage are mitigated.4   
Piroxicam is a member of class II of Biopharmaceutics Classification System (BCS) of 
drugs.5 The substances included in this class are either completely insoluble or meagrely soluble 
in the aqueous fluids; however, they possess remarkable ability to traverse cell membranes 
efficiently.6 Piroxicam is scarcely soluble in the aqueous media as it imparts about 23 µg/mL 
solubility in water.7 Water is the main component of gastrointestinal (GI) fluid. A BCS class II 
entity is meagrely dissolved in GI fluid present in the lumen of the GIT. Only the drug in solution 
state in GI fluid can traverse cells.8 Owing to exiguous solubility in GI fluid, piroxicam is not 
sufficiently permeated through cells; hence, the drug titer in the systemic circulation is not effective 
to block the activity of COX type I and COX type II enzymes well. An alternative way to achieve 
the effective bioavailability is to administer the drug at higher quantity; however, this may induce 
severe deleterious effects in the GIT. Thus, adoption of a suitable solubility improving technique 
is a more sagacious way to cope with this problem. 
Solubility of a BCS class II substance can be ameliorated via several techniques such as 
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fabrication of nano-sized drug-loaded hydrophilic particles, dispersion of a drug in hydrophilic 
polymers, association of a drug with cyclodextrins, wrapping a drug payload core in a hydrophilic 
wall material, casting of drug-laden porous silica particles, self-emulsifying systems, 
microemulsions, co-crystallization and others.6,9-11 Pharmaceutical nanoencapsulation is a 
promising technology for resolving poor solubility and bioavailability problems of a BSC class II 
agent. It is an approach to enwrap a solid, liquid or gaseous substance in diminutive polymeric 
capsules.12 In this drug delivery system, the wrapper or wall material protects the core from the 
surrounding environment, and storage stability of the payload can be extended.13 Gelatin, a 
heterogeneous mixture of chains of amino acids, is soluble in warm water. It is derived from 
collagen protein by hydrolysis. It is broadly availed in pharmaceutical, food and cosmetic 
industries owing to its absolutely non-toxic, biodegradable, ecofriendly, biocompatible and high 
payload holding characteristics. Also, it is convenient to administer and eliminates appropriately 
in physiological milieu.14 It is a regularly utilized wrapping or wall material for encapsulation of 
pharmacologically active substances and nutrients.15 A number of previous studies have shown 
that gelatin can foster the aqueous solubility and oral bioavailability of numerous drugs.9,16 A 
hydroalcoholic compound solution of a BCS class II drug and gelatin can be transmuted to a dry 
particulate form by the electrospraying technique. In this process, water is evaporated to a great 
deal and the ethanolic solution of the drug (core) is enwrapped or encapsulated by gelatin (shell or 
wall).12,17 Electrospraying is an excellent technique to obtain drug-loaded spherical gelatin 
nanocapsules.18 A pharmaceutical nanocapsule is a nano-sized (< 1 µm) drug-loaded spherical 
particle having a core-shell morphology.19  
The aim of this work was to augment the aqueous solubility and release rate of piroxicam 
using gelatin nanoencapsulation method. Thus, PLGNs were prepared by the electrospraying 
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technique. Solubility and release rate of piroxicam in PLGNs were investigated. The crystalline 
physiognomies were determined using PXRD and DSC methods. TGA was executed for 
measuring percent weight loss occurring in a sample owing to gradually rising temperature. FTIR 
spectroscopic analyses were carried out for exploring possible interlinkage between piroxicam and 
gelatin. The shapes and surface attributes of particles were inspected using a SEM. Oral 
bioavailability was evaluated in white albino laboratory rats (Sprague Dawley rats). Area under 
the curve (AUC), the highest drug titer in plasma (Cmax) and time taken from dose administration 
to the appearance of Cmax (Tmax) were used as parameters for assessing bioavailability. 
 
Materials and methods 
Materials 
Piroxicam (purity ≥ 98%) was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Gelatin was procured from Daejung Chemical Co. (Siheung, South Korea). All other chemicals 
and solvents were of reagent grade. 
Preparation of PLGNs 
All the formulations were prepared via the electrospraying technique. The recipe of samples 
prepared in this study is shown in Table 1. For each sample, 100 mg PPDP was completely 
dissolved in 60 mL ethanol at 40°C (solution A). Gelatin was dissolved separately in 90 mL 
distilled water at 40°C (solution B). Then, both the solutions were mixed together thoroughly to 
get a final clear solution (solution C). The quantities of solvents in solution A and solution B were 
taken so that the composition of solvent in solution C was approximately 40% hydroalcoholic 
mixture. Solution C was sprayed under the influence of a high voltage using an electrospraying 
machine (Model ESR 100, NanoNC equipment; Seoul, South Korea). The compound solution to 
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be electrospun was filled in the barrel of a syringe made up of glass (Hamilton Co., Reno, NV, 
USA). The solution-loaded syringe was properly attached to the syringe holder. The plunger of the 
syringe was pushed by the pump to move the solution via a single-lumen nozzle at a constant rate 
of 1 mL/h. At the voltage of 12.5 kV, Taylor cone was formed and the jet was converted to plume 
beneath the Taylor cone. Each electrospun sample was collected and placed at 40°C until constant 
weight, and stowed in air-tight microtubes. 
Solubility of piroxicam in PLGNs 
For each PLGN formulation, excess of dried product was poured into a 2 mL capacity 
Eppendorf microtube containing 0.5 mL distilled water and mixing was done for a minute using a 
vortex-mixer. Then, microtubes were swayed (100 rpm) for 5 days in a water-bath (37°C). After 
5 days, the samples were centrifuged at 7000 ×g for 5 minutes. In another clean microtube, 0.2 mL 
of clear supernatant was poured and diluted with equal quantity of acetonitrile. The diluted sample 
(10 µL) was analysed by a 1260-Infinity HPLC equipment (Agilent Technologies, CA, USA) using 
a QuasarTM C18 column (4.6 mm I.D. × 150 mm, 5 μm) (PerkinElmer, Shelton, CT, USA) set at 
40°C. The mobile phase was comprising of trifluoroacetic acid and acetonitrile (60:40, v/v), which 
eluted at a rate of 1 mL/min. The eluent was quantified at 332 nm for the determination of 
piroxicam concentration.20 
Content of piroxicam in PLGNs 
A PLGN formulation, equivalent to 5 mg piroxicam, was transferred to a 100 mL 
volumetric flask containing 100 mL of 40% aqueous ethanol. The lid was tightly closed to 
minimize the evaporation of the solvent. Then, the flask was secured in a water-bath (37°C) for 2 
hours. The solution was cleared by magnetic stirring. Thus, a stock solution of 50 µg/mL drug 
concentration was obtained. This clear solution was filtered (0.45 μm) and aptly diluted with 
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acetonitrile. The dilution was analysed in accordance with the above-mentioned HPLC method for 
determining actual concentration of the drug. The content of piroxicam in each PLGN sample was 
computed using the following formula: PC = PA/PT × 100. Where, PC stands for piroxicam amount 
in the sample, PA stands for actual quantity of piroxicam in the diluted sample, and PT stands for 
the theoretical quantity of the dilution. For each composition, the test was performed in triplicate 
(n = 3). 
Drug loading 
The percentage of piroxicam loading was computed by using the following formula: PL = 
PW/PN × 100. Where, PL is the percentage of piroxicam loading to PLGN, PW is the weight of 
piroxicam in grams present in PN of PLGN, and PN is the quantity of PLGN in grams.  
Encapsulation efficiency 
The optimized PLGN formulation, equivalent to 5 mg drug, was placed in 2 mL capacity 
Amicon® ultra-2 centrifugal filter (UFC200324, MWCO 3000 Da, Merck Millipore, Billerica, 
MA, USA) and rinsed thrice with absolute alcohol, each time with 1 mL volume. The filtrate was 
discarded each time. The ultracentrifugal filtration was accomplished with 7000 ×g RPMs for 10 
min.  Then, the residue was dissolved gradually with 40% hydroalcoholic solution which was 
preheated at 50°C. Each time, 1 mL volume was used until complete dissolution. The filtrate was 
preserved in 10 mL capacity measuring flask each time. Then, the volume was made 100 mL with 
ethanol. The theoretical concentration of this solution was 50 µg/mL. The actual concentration of 
piroxicam in this solution was determined by the HPLC method as described above. The 
encapsulation efficiency of PLGN was calculated by using following formula: EE = PE/PT ×100, 
where, EE is the encapsulation efficiency, PE is the actual quantity in grams of encapsulated 
piroxicam, and PT is the total grams of piroxicam present in PLGN in accordance with the drug 
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content. 
Release rate of piroxicam from PLGNs 
Release rate of piroxicam from a PLGN formulation was determined using the basket 
apparatus (Model Vision Classic 6, Hanson Research Co., CA, USA). A PLGN formulation 
corresponding to 40 mg piroxicam was sealed in a dialysis pouch (12K-14K Da). Then, the 
sample-loaded pouch was encaged in the basket by fitting the basket with the shaft. In order to 
sink the basket in 900 mL of 2% (w/v) aqueous solution of Tween 80 filled in the vessel below, 
the rotating shaft (100 rpm) was pulled down. The temperature of the release medium was already 
maintained at 37 ± 0.5°C. After each predetermined time interval, 1 mL of release medium was 
sampled using a syringe, and filtered into an HPLC vial using a syringe filter (0.22 μm). Piroxicam 
concentration was quantified by the above-mentioned HPLC method. For each PLGN formulation, 
experiment was done in sextuplicate (n = 6). 
X-ray diffraction 
A D-MAX 2500PC X-ray diffractometer (Rigaku Corporation, Tokyo, Japan), using a CuKα1 
monochromatic emission source, was used for determining the degree of crystallinity or 
amorphousness of the samples. The analyses were carried out in the range of 5°-50° at a scanning 
speed of 10°/min with a step-size of 0.02°/sec and scanning mode set at 2θ. The current flow and 
voltage supply were regulated at100 mA and 100 kV, respectively. 
Differential scanning calorimetry 
A DSC-Q20 differential scanning calorimeter (TA Instruments Co.; New Castle, DE, USA) 
was employed for confirming the crystalline or amorphous status and the other thermal 
physiognomies of the samples. About 5 mg quantity of a sample to be tested was placed and sealed 
in a Tzero aluminum crucible (TA Instruments Co.; New Castle, DE, USA). The sealed sample 
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was placed in the calorimeter which was catered with a constant supply of nitrogen (30 cm3/min). 
The scanning was performed by heating the sample in the range of 30°-300°C at the rate of 
10°C/min. 
Thermogravimetric Analysis 
The decrease in weight of a sample occurring with gradual raise in temperature was 
determined by a TGA Q50 TG analyzer (TA Instruments Co.; New Castle, DE, USA). About 5 mg 
quantity of a sample, put into the hangable platinum crucible, was lowered into the furnace by the 
automatic moving arm. The sample enclosed in the furnace was gradually heated in the range of 
50-550°C at the heating speed of 10°C/min and in the constant supply of nitrogen (25 cm3/min). 
The decrease in weight (%) of the sample was noted. 
Scanning electron microscopy 
An S-4800 scanning electron microscope (Hitachi, Japan) was employed for studying the 
shape, size and surface quality of the particles. The samples to be inspected were clung on the 
exposed surface of a double-side adhesive tape affixed to a brass stub. Then, the samples were 
coated with platinum (Emitech K-575-K Ion-Sputter Coater) under 8×10-3 mbar vacuum. The 
current supply and turbo speed settings were adjusted at 20 mA and 90%, respectively. The coated 
samples were scanned by SEM and images were recorded. 
Fourier transform infrared spectroscopy 
FTIR spectra of the samples were recorded in the range of 4000-400 cm-1 at the resolution 
of 2 cm-1 using a Nicolet-6700 FTIR spectrophotometer (Thermo Scientific, PA, USA).  
Bioavailability assessment in rats 
Acclimatization of animals – Twelve white albino laboratory rats (Sprague Dawley rats), 
each of 260-300 g body weight, were divided into two equal groups. They were kept in cages 
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placed under controlled environment of 21-28°C temperature and 45-65% relative humidity. 
Before giving a dose of PPDP or PLGN formulation via the oral route, each one was fasted for 
1.0-1.5 day; nevertheless, access to drinking water was not discontinued. All the steps involved in 
exploitation of animals as experimental organisms in research were conducted strictly following 
the ‘Guiding Principles in the Use of Animals in Toxicology’ recommended by the Society of 
Toxicology, and NIH policy regarding the animal welfare. All the protocols were also reviewed 
by the Institutional Animal Care and Use Committee (IACUC) of Government College University 
Faisalabad prior to granting the approval of the study (Ref. No. GCUF/ERC/2138). 
Arterial intubation for blood sampling – Each fasted animal was anesthetized by injecting a 
mixture of tiletamine and xylazine (2/1, v/v) intramuscularly. Cannulation of a polyethylene tube 
into the right carotid artery was accomplished surgically. The tube was passed through the hollow 
spring attached with the infusion harness in order to protect it from likely damage by the animal. 
Each harnessed rat was kept in a separate adequate-sized cage where it was able to move freely. 
Dose administeration – A dose of PPDP or optimized PLGN formulation, corresponding to 7 
mg/kg weight, was suspended in 700 μL water and promptly given to a harnessed rat through the 
oral route using an oral gavage. 
Blood collection, plasma separation and storage – A 200 μL aliquot of blood was withdrawn from 
the carotid artery of a cannulated rat with the help of 1 mL capacity heparinized syringe at each of 
the following time points: 1, 2, 3, 4, 5, 6, 12, 24, 36 and 48 h. Plasma was separated tout de suite 
by centrifugation at 5000 ×g for 10 min. Subsequently, the plasma samples were preserved at -
20°C until further experimentations. 
Extraction and HPLC analysis – A 50 µL plasma quantity was poured in a 2 mL capacity 
microtube and an aliquot (20µg/ml) of naproxen sodium was added to it as an internal standard. 
Subsequently, 700 µL of acetonitrile were added to it as a menstruum for liquid-liquid extraction. 
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After a thorough mixing, centrifugation was performed at 5000 ×g for 3 min. Then, the clear 
supernatant was carefully shifted to a small volume HPLC vial and analyzed in accordance with 
the method as described above. 
Calculation of pharmacokinetic parameters – The pharmacokinetic parameters, such as  area under 
the curve (AUC, h.µg/mL), the highest piroxicam titer in plasma (Cmax, µg/mL) and time taken 
from dose administration to the appearance of Cmax (Tmax, h), were computed employing a non-
compartmental analysis (PK Solver, version 2.0, Pharsight Co., CA, USA) following linear 
trapezoidal method.21 Corresponding to each time point, the level of significance (p-value) 
between two means of piroxicam concentrations was determined using the Student t-test. In 
general, a p-value less than 0.05 suggests presence of a significant difference. On the other hand, 
a p-value more than 0.05 represents a nonsignificant difference. 
Results and discussion 
Gelatin is a hydrophilic polypeptide which has been used extensively in encapsulation of 
BCS class II drugs so as to enhance their solubility and oral bioavailability.12,22 Polymeric 
nanoparticulated drug delivery systems also improve solubility, dissolution rate and oral 
bioavailability of such drugs.9,23 A drug-laden entity owning measurements of less than 1 µm is 
considered to be a pharmaceutical nanoparticle.19 Electrospraying technique is an awesome way 
to obtain drug-loaded polymeric nanoparticles.8,23 Thus, in this research PLGNs were prepared 
using the electrospraying technique. A recipe of each nanocontainer sample is given in Table 1. 
The outcomes of the aqueous solubility of piroxicam in PLGNs are shown in Fig. 1. 
Solubility of piroxicam in samples I-IV was augmented as the drug/gelatin ratio increased to 1/8 
(w/w). This was owing to enhanced wettability of the drug by hydrophilic gelatin. As the 
drug/gelatin ratio increased in samples V-VII from 1/10 (w/w) to 1/20 (w/w), an apparent reduction 
in solubility was noticed. Even so, the solubility outcomes were not significantly different (p > 
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0.05) amongst them. The presence of relatively higher proportion of gelatin against the drug in the 
formulation eventuated in supersaturation more quickly; wherefore, no further formulation was 
dissolved. The drug was enwrapped or encapsulated in the gelatin shell; thus, no further drug was 
dissolved too. For that reason, samples V, VI and VII containing relatively larger quantities of 
gelatin furnished ostensibly decreased solubility of piroxicam. The PLGN formulation IV 
exhibited apparently the highest solubility of piroxicam which was 600-times higher than that 
shown by PPDP (94.24 ± 25.65 µg/mL vs. 0.16 ± 0.21 µg/mL). Furthermore, solubility of 
piroxicam furnished by the corresponding physical mixture (PM) was 29.53 ± 24.34 µg/mL which 
was less than that shown by the optimized formulation. The PM was prepared by simply triturating 
piroxicam and gelatin in 1/8 (w/w) ratio using a pestle and mortar. 
 The piroxicam content in the optimized PLGN formulation was 93.41± 0.56 %. The high 
drug content was owing to the solvent-evaporation method. In this approach, all the constituents 
of a formulation are first entirely dissolved in a solvent system to get a transparent homogeneous 
mixture and then subjected to drying; thus, drug/excipient ratio is not affected even if some of the 
solution is spilt accidentally. This method also ensures high content uniformity as molecular level 
mixing is achieved when a clear solution is formed. Moreover, drug loading in the optimized 
formulation was 10.45 ± 0.06%. 
The encapsulation efficiency calculated was 66.74 ± 6.87%. The optimized PLGN 
formulation was rinsed thrice with absolute ethanol because the free drug is soluble in absolute 
ethanol while gelatin is insoluble in absolute ethanol. Thus, free drug was percolated with filtrate 
and encapsulated drug remained preserved inside gelatin shell. Furthermore, 40% hydroalcoholic 
solution at 50°C was used for dissolving the residue and leaching of encapsulated drug because 
gelatin is soluble in 40% aqueous ethanol at 35-40°C 12. 
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The release rate of piroxicam from the PLGNs is shown in Fig. 2. All the formulations 
showed higher dissolution of the payload as compared to PPDP. The improved release of the drug 
from the formulations might be credited to enhanced wetting and conversion of piroxicam to the 
amorphous counterpart by gelatin. Gelatin hinders recrystallization of the drug from solution. The 
amorphous drug bears more surface area exposed to surrounding medium; accordingly, fostering 
the release consequently. Amongst all the trialed formulations in this study, PLGN formulation IV 
consisting of drug/gelatin (1/8, w/w) exhibited the most expedited release rate. In particular, the 
release rate was about 7-fold higher than that of PPDP (85.12 ± 10.96% vs. 11.81 ± 5.34%) and 3-
fold as compared to PM (85.12 ± 10.96% vs. 29.56 ± 6.52%) in 10 minutes. The release profile of 
piroxicam pertaining to PM was erratic. The release rate of the drug was gradually decreased with 
increasing drug/gelatin ratio from 1/10 (w/w) to 1/20 (w/w) in formulations V to VII, respectively. 
This might be ascribed to the existence of relatively thicker gelatin shell around the core which a 
little bit delayed the drug release. Based on the highest apparent solubility and release rate, PLGN 
sample IV was opted for further characterization. 
The degree of crystallinity was scrutinized using PXRD system and further confirmed by 
DSC. The PXRD pattern of PPDP represented its particular crystalline nature (Fig. 3A). The 
distinguishing spikes of piroxicam appeared at 8.58°, 11.73°, 14.54°, 16.69°, 17.62°, 18.78°, 
21.76°, 22.48° and 27.40°. The absence of any sharp-pointed projection in the pattern of gelatin 
confirmed its amorphous nature (Fig. 3B). The distinctive barbs of piroxicam were also noticed in 
the pattern of PM (Fig. 3C) which suggested that the drug retained its crystalline disposition in 
PM. On the other hand, the spikes corresponding to piroxicam vanished in the pattern of PLGN 
formulation IV (Fig. 3D).  This suggested that piroxicam lost its inherent crystalline property 
during the preparation of PLGNs and embraced amorphous one after loading. The conclusions 
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obtained by DSC analyses were in accord with those given by PXRD analyses. A sharp endotherm 
emulating the melting point of piroxicam was seen at 200°C in the thermogram of PPDP (Fig. 4A) 
which confirmed its particular crystalline disposition. Thermogram of gelatin was devoid of any 
sharp endotherm (Fig. 4B), yet, a wide curve steeping downward was seen in the range of 30-
180°C which was owing to consumption of heat for vaporizing moisture present in the sample. A 
sharp endotherm emulating the melting point of the drug at 200°C and the broad curve steeping 
downward in the range of 30-180°C were seen in the thermogram of PM (Fig. 4C). This confirmed 
that piroxicam did not transmute its crystalline disposition in PM. On the other hand, both of these 
endothermic behaviours were not present in the thermogram of PLGN sample IV (Fig. 4D). This 
suggested that the encapsulated drug was in the amorphous state and the formulation prepared was 
completely dry. The conversion to the amorphous state might be ascribed to the influence of gelatin 
in the formulation and the preparation method.24 
TGA thermograms recorded in the range of 50-550°C are revealed in Fig. 5. There is only 
10% loss in weight up to 230°C due to escape of physically attached moisture. Approximately, 3% 
degradation of PPDP occurred in the range of 50-250°C (Fig. 5A). Then, 71% further sudden 
degradation of PPDP was observed in the range of 250-300°C. Overall, 88% PPDP was degraded 
in the range of 50-550°C. In the case of gelatin, 7% weight loss was observed in the range of 50-
200°C (Fig. 5B). About 44% further degradation of gelatin was seen in the range of 200-300°C. 
In total, 67% degradation of gelatin took place in the range of 50-550°C. The PM showed 6% 
weight loss in the range of 50-180°C followed by 56% further weight loss in the range of 180-
350°C, and total weight loss was about 69% in the range of 50-550°C (Fig. 5C). In the case of 
PLGN, only 1% weight loss occurred in the range of 50-180°C, next 40% weight loss took place 
in the range of 180-350°C, and 48% total weight loss was noticed in the range of 50-550°C (Fig. 
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5D). The comparison of TGA thermogram of PM with that of PLGN suggested that the 
encapsulated drug was thermally more stable. Gelatin (wall material) performs as a protective 
shield for the encapsulated  products (core content) and thereby prolongs the shelf-life of the 
products.13 
Scanning electron micrographs of PPDP (Fig. 6A) and gelatin (Fig. 6B) showed particles 
with irregular contours and surface features. Each round-shaped particle of PLGN formulation IV 
was bearing a dimple on one side and exhibited an unwrinkled surface (Fig. 6C). A pharmaceutical 
nanocapsule is a nano-sized (≤1000 nm) drug-loaded spherical particle having a core-shell 
morphology. From Fig. 6C, it can be observed that the particle-size of all the shown particles is 
less than 1000 nm. Thus, particles of electrosprayed PLGN formulation IV were nanocontainers. 
A smooth surface of the particles of PLGN and a core-shell morphology is shown in Fig. 6D. 
FTIR spectra are shown in Fig. 7. The spectrum of PPDP revealed sharp distinctive spikes 
mainly in the fingerprint region at 452 cm-1, 527 cm-1, 560 cm-1, 581 cm-1, 611 cm-1, 686 cm-1, 733 
cm-1, 758 cm-1, 825 cm-1, 876 cm-1, 936 cm-1, 1145 cm-1, 1180 cm-1, 1345 cm-1, 1435 cm-1 and 
1529 cm-1, and at 3338 cm-1. Other peaks appeared at 1575 cm-1 and 1630 cm-1 (Fig. 7A). The 
absorption band appearing at 3338 cm-1 was owing to valence vibrations of hydroxyl groups (-
OH) and secondary amide groups (-NH).25,26 Absorption bands corresponding to the conjugating 
benzene and pyridine rings are situated in the range of 1650-1550 cm-1.27 The band appearing at 
1630 cm-1 was due to valence vibrations of carbonyl group (C=O) of the secondary amides while 
a high intensity band at 1529 cm-1 was because of deformation vibrations of amide groups (-NH). 
The bands located at 1575 cm-1 and 1435 cm-1 are due to valence vibrations (C=C) of benzene and 
pyridine rings. The presence of sulphur dioxide (SO2) group in piroxicam was confirmed by the 
bands located at 1345 cm-1 and 1180 cm
-1 arising from the asymmetric and symmetric valence 
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vibrations, respectively. The spikes appearing at 876 cm-1, 825 cm-1 and 758 cm-1 were 
characteristic peaks of deformation vibrations in the plane (C-H) of aromatic rings present in 
piroxicam. FTIR spectrum of gelatin is shown in Fig. 7B. All the distinctive spikes of piroxicam 
mentioned above were also witnessed at the same positions in both the spectra of PM (Fig. 7C) 
and PLGN formulation IV (Fig. 7D). Moreover, the spectrum of PM was identical to that of the 
formulation IV; therefore, this suggested non-existence of interactions between piroxicam and 
gelatin. 
Figure 7 reveals the mean piroxicam concentration-time graphs constructed with the data 
regarding oral administration of PPDP (Fig. 8A) and PLGN formulation IV (Fig. 8B). The 
formulation resulted in higher mean plasma concentrations of piroxicam at all time intervals 
between 1-48 h (t-test, p < 0.05) than did PPDP. The pharmacokinetic attributes, such as AUC, 
Cmax and Tmax, are displayed in Table 2. The AUC and Cmax with formulation IV were significantly 
ameliorated as compared to those obtained with PPDP (t-test, p < 0.05); nevertheless, Tmax did not 
alter significantly (t-test, p > 0.05). As compared with PPDP, bioavailability was ~ 4-fold with 
PLGN formulation IV. The better bioavailability can be credited to augmented solubility and 
dissolution of piroxicam due to improved wetting by gelatin, nanosizing and transmutation of the 
inherent crystalline structure of the drug to the amorphous one. Thus, this formulation consisting 
of piroxicam/gelatin (1/8, w/w) might be an important bioavailability-enhancing system for 
delivery of piroxicam orally. 
 
Conclusion 
PLGN formulation IV, consisting of piroxicam and gelatin at the ratio of 1/8 (w/w), provided 
the most boosted apparent solubility (94.24 ± 25.65 µg/mL) and release rate (85.12 ± 10.96% in 
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10 min). The solubility was 600-times higher than that of PPDP and 3-fold as compared to PM. 
Moreover, release rate was 7-fold and 3-fold higher, respectively. The drug content, drug loading 
and encapsulation efficiency of this formulation were 93.41± 0.56%, 10.45± 0.06% and 66.74± 
6.87%, respectively.  The encapsulated amorphous piroxicam exhibited more stability, and had no 
covalent linkage with gelatin. The reinforcement in solubility and dissolution of piroxicam in water 
can be owing to improved wetting of piroxicam due to the presence of gelatin and conversion of 
piroxicam from its crystalline structure to the amorphous one in PLGN. The amelioration in 
dissolution rate and solubility of piroxicam in PLGN lead to greater bioavailability of piroxicam. 
As compared with PPDP, enhancement in bioavailability with PLGN formulation IV was 4-fold. 
Thus, this formulation is a prospective bioavailability enhancing drug delivery system for 
administeration of piroxicam via the oral routre. 
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Table 1. Compositions of PLGNs.  
Constituents (w/w) I II III IV V VI VII 
Piroxicam 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Gelatin 1.0 2.0 4.0 8.0 10.0 15.0 20.0 
PLGNs = piroxicam-loaded gelatin-nanocontainers. 
 
 
Table 2. Pharmacokinetic parameters obtained after oral administration. 
Parameter PLGN formulation IV PPDP 
AUC(0-∞) (h· g/ml) 
Cmax (g/ml) 
971.13 ± 185.74* 
61.04 ± 15.38* 
251.42 ± 214.10 
15.13 ± 8.88 
Tmax (h) 5.00 ± 0.00 5.00 ± 1.00 
t1/2 (h)    10.40 ± 2.85 15.28 ± 3.00 
Kel (h
-1) 0.07 ± 0.01 0.05 ± 0.01 
MRT(0-∞) (h) 16.02 ± 1.42 17.73 ± 9.39 
Each value represents the mean ± SD (n=6). *P<0.05 compared with PPDP. 
PLGN = piroxicam-loaded gelatin-nanocontainer; PPDP = piroxicam plain drug powder. 
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Figure Legends 
Fig. 1. Effect of composition on the aqueous solubility of piroxicam in piroxicam-loaded gelatin-
nanocontainers (PLGNs). Solubility of piroxicam plain drug powder (PPDP) and physical 
mixture (PM) in water is also shown. Each value shows the mean ± SD (n=3). 
Fig. 2. Effect of composition on release rate of piroxicam from piroxicam-loaded gelatin-
nanocontainers (PLGNs). Dissolution with piroxicam plain drug powder (PPDP) and 
physical mixture (PM) is also shown. Each value shows the mean ± SD (n=6). 
Fig. 3. PXRD patterns: (A) piroxicam plain drug powder (PPDP), (B) gelatin, (C) physical mixture 
(PM) and (D) piroxicam-loaded gelatin-nanocontainers (PLGNs). 
 Fig. 4. DSC thermograms: (A) piroxicam plain drug powder (PPDP), (B) gelatin, (C) physical 
mixture (PM) and (D) piroxicam-loaded gelatin-nanocontainers (PLGNs). 
Fig. 5. TGA thermograms: (A) piroxicam plain drug powder (PPDP), (B) gelatin, (C) physical 
mixture (PM) and (D) piroxicam-loaded gelatin-nanocontainers (PLGNs). 
Fig. 6. SEM images: (A) piroxicam plain drug powder (PPDP) (× 5000), (B) gelatin (× 300), (C) 
piroxicam-loaded gelatin-nanocontainers (PLGNs) (× 15,000) and (D) core-shell 
morphology of PLGNs. 
 Fig. 7. FTIR spectra: (A) piroxicam plain drug powder (PPDP), (B) gelatin, (C) physical mixture 
(PM) and (D) piroxicam-loaded gelatin-nanocontainers (PLGNs). 
 Fig. 8. Piroxicam mean titer in plasma versus time graphs: (A) piroxicam plain drug powder 
(PPDP) and (B) piroxicam-loaded gelatin-nanocontainers (PLGNs). *P<0.05 as compared 
to PPDP. 
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Figure 8 
 
 
Time ( hrs )
0 4 8 12 16 20 24 28 32 36 40 44 48
P
ir
o
x
ic
am
 c
o
n
c
en
tr
at
i o
n
 i
n
 p
la
sm
a 
( 
g
/m
l 
)
0
10
20
30
40
50
60
70
80
90
A
B
*
*
*
*
*
*
*
 
 
